FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ernest Borden

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Mouse

Activities & Behaviors

Drug Evaluation

Physiology

Anatomy

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Drug Administration Schedule

Co-author Network

Publications

TOP 3
Keman Zhang; Ernest C Borden; Jiaqi Duan; Barbara Jacobs; Poki Wong; Barbara Bedogni
An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Daniel J Lindner; Ralph Tuthill; Yan Wu; John P Fruehauf; Rebecca Haney; Barbara S Jacobs; Ernest C Borden
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
Ernest C Borden; Afshin Dowlati
Phase I trials of targeted anticancer drugs: a need to refocus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ernest Borden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Keman Zhang; Ernest C Borden; Jiaqi Duan; Barbara Jacobs; Poki Wong; Barbara Bedogni
An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Pigment cell & melanoma research 2013;26(3):408-14.
2013: Daniel J Lindner; Ralph Tuthill; Yan Wu; John P Fruehauf; Rebecca Haney; Barbara S Jacobs; Ernest C Borden
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
Matrix biology : journal of the International Society for Matrix Biology 2013;32(2):123-32.
2012: Ernest C Borden; Afshin Dowlati
Phase I trials of targeted anticancer drugs: a need to refocus.
Nature reviews. Drug discovery 2012;11(12):889-90.
2012: Venugopalan Cheriyath; Erinn Downs-Kelly; P Elson; P Evangelista; Barbara S Jacobs; M A Kuhns; R Tubbs; Ernest C Borden
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.
Oncogene 2012;31(17):2222-36.
2012: Pierre L Triozzi; Susan Achberger; Wayne Aldrich; Ronald Grane; Arun D Singh; Ernest C Borden
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
Journal of translational medicine 2012;10():241.
2011: Taolin Yi; Thomas G Budd; Paul Elson; Emese Hollovary; Barbara Jacobs; Masato Mitsuhashi; Timothy Spiro; Pierre Triozzi; Ernest C Borden
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Oncotarget 2011;2(12):1155-64.
2011: Pierre L Triozzi; Ernest C Borden
VB-111 for cancer.
Expert opinion on biological therapy 2011;11(12):1669-76.
2011: Baisakhi Raychaudhuri; Patricia Rayman; Joanna Ireland; Jennifer Ko; Brian Rini; Ernest C Borden; Jorge Garcia; Michael A Vogelbaum; James Finke
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
Neuro-oncology 2011;13(6):591-9.
2011: Ernest C Borden; Barbara Jacobs; Emese Hollovary; Lisa Rybicki; Paul Elson; Thomas Olencki; Pierre L Triozzi
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011;31(5):433-40.
2011: Venugopalan Cheriyath; M A Kuhns; Matt Kalaycio; Ernest C Borden
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
British journal of cancer 2011;104(6):957-67.
2011: Ernest C Borden; Bryan R Williams
Interferon-stimulated genes and their protein products: what and how?
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011;31(1):1-4.
2011: Venugopalan Cheriyath; Douglas W Leaman; Ernest C Borden
Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011;31(1):173-81.
2010: Xiaoxia Z West; Nikolay L Malinin; Alona A Merkulova; Mira Tischenko; Bethany A Kerr; Ernest C Borden; Eugene A Podrez; Robert G Salomon; Tatiana V Byzova
Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands.
Nature 2010;467(7318):972-6.
2010: Wioleta Luszczek; Venugopalan Cheriyath; Tarek Mekhail; Ernest C Borden
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Molecular cancer therapeutics 2010;9(8):2309-21.
2010: Ernest C Borden; Derek Raghavan
Personalizing medicine for cancer: the next decade.
Nature reviews. Drug discovery 2010;9(5):343-4.
2008: Ernest C Borden; Harriet M Kluger; John Crowley
Apoptosis: a clinical perspective.
Nature reviews. Drug discovery 2008;7(12):959.
2008: Kevin L Taylor; Douglas W Leaman; Ron Grane; Nadir Mechti; Ernest C Borden; Daniel J Lindner
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(12):733-40.
2008: Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H C Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5360-7.
2008: Sujith R Kalmadi; Cathryn Rankin; Michael J Kraut; Andrew D Jacobs; Daniel P Petrylak; David J Adelstein; Mary-Louise Keohan; Robert N Taub; Ernest C Borden
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Lung cancer (Amsterdam, Netherlands) 2008;60(2):259-63.
2008: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; ROBERT G MAKI; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):626-32.
2008: Soo In Bae; Venugopalan Cheriyath; Barbara S Jacobs; Frederic J Reu; Ernest C Borden
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Oncogene 2008;27(4):490-8.
2007: Ernest C Borden
Melanoma 2007: current state and preview of the future.
Seminars in oncology 2007;34(6):449-51.
2007: Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Interferons at age 50: past, current and future impact on biomedicine.
Nature reviews. Drug discovery 2007;6(12):975-90.
2007: Venugopalan Cheriyath; Keith B Glaser; Jeffrey F Waring; Rachid Baz; Mohamad A Hussein; Ernest C Borden
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
The Journal of clinical investigation 2007;117(10):3107-17.
2007: Ernest C Borden
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.
Cytokine & growth factor reviews 2007;18(5-6):491-501.
2007: Jing Li; Daniel J Lindner; Carol Farver; Ernest C Borden; Taolin Yi
Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Cancer chemotherapy and pharmacology 2007;60(3):341-9.
2007: Linda L Garland; Cathryn Rankin; David R Gandara; Saul E Rivkin; Katherine M Scott; Raymond B Nagle; Andres J P Klein-Szanto; Joseph R Testa; Deborah A Altomare; Ernest C Borden
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2406-13.
2007: Sujith Kalmadi; Mellar Davis; Afshin Dowlati; S O'Keefe; M Cline-Burkhardt; Robert Pelley; Ernest C Borden; Robert Dreicer; Ronald Bukowski; Tarek Mekhail
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Investigational new drugs 2007;25(3):211-6.
2007: Paul Masci; Thomas Olencki; L Wood; Lisa Rybicki; B Jacobs; B Williams; P Faber; Ronald Bukowski; K Tong; Ernest C Borden
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Clinical pharmacology and therapeutics 2007;81(3):354-61.
2007: Ernest C Borden
Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research.
Oncology (Williston Park, N.Y.) 2007;21(2):247-9.
2007: Jeff M Hsing; Snehal G Thakkar; Ernest C Borden; G Thomas Budd
Intimal pulmonary artery sarcoma presenting as dyspnea: case report.
International seminars in surgical oncology : ISSO 2007;4():14.
2006: Snehal G Thakkar; David M Peereboom; Thomas Olencki; Barbara Jacobs; Paul Elson; Lisa Rybicki; Daniel J Lindner; Ernest C Borden
Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006;26(11):800-3.
2006: G Thomas Budd; Massimo Cristofanilli; Matthew J Ellis; Alison T Stopeck; Ernest C Borden; M Craig Miller; Jeri Matera; Madeline Repollet; Gerald V Doyle; Leon W M M Terstappen; Daniel F Hayes
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6403-9.
2006: Frederic J Reu; Soo In Bae; Leonid Cherkassky; Douglas W Leaman; Daniel J Lindner; Normand Beaulieu; A Robert MacLeod; Ernest C Borden
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(23):3771-9.
2006: Jesper B andersen; Jesper Andersen; Ernest C Borden; Olga Goloubeva; Bret A Hassel; Torben F Orntoft
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer.
British journal of cancer 2006;94(10):1465-71.
2006: Kevin L Taylor; Rhonda K Oates; Ronald W Grane; Douglas W Leaman; Ernest C Borden; Daniel J Lindner
IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006;26(5):353-61.
2006: Warren A Chow; Victoria Bedell; Popsie Gaytan; Ernest C Borden; John Goldblum; David Hicks; Marilyn L Slovak
Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas.
Cancer genetics and cytogenetics 2006;166(2):95-100.
2006: Frederic J Reu; Douglas W Leaman; Ratan R Maitra; Soo In Bae; Leonid Cherkassky; Mark W Fox; Donald R Rempinski; Normand Beaulieu; A Robert MacLeod; Ernest C Borden
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Cancer research 2006;66(5):2785-93.
2006: Gary Von Burton; Cathy Rankin; Mark M Zalupski; Glen M Mills; Ernest C Borden; Antman Karen
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
American journal of clinical oncology 2006;29(1):59-61.
2005: Keke Fan; Ming Zhou; Manas K Pathak; Daniel J Lindner; Cengiz Z Altuntas; Vincent K Tuohy; Ernest C Borden; Taolin Yi
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(10):7003-8.
2005: Nadia V Giannakopoulos; Jiann-Kae Luo; Vladimir Papov; Weiguo Zou; Deborah J Lenschow; Barbara S Jacobs; Ernest C Borden; Jun Li; Herbert W Virgin; Dong-Er Zhang
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.
Biochemical and biophysical research communications 2005;336(2):496-506.
2005: Ernest C Borden
Review: Milstein Award lecture: interferons and cancer: where from here?
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2005;25(9):511-27.
2005: David Weng; Paul Masci; Susan F Radka; T Elise Jackson; Patricia A Weiss; Ram Ganapathi; Paul Elson; William B Capra; Vann P Parker; Jennifer A Lockridge; J Wayne Cowens; Nassim Usman; Ernest C Borden
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.
Molecular cancer therapeutics 2005;4(6):948-55.
2005: Ama Z S Rohatiner; Walter Gregory; B Peterson; Ernest C Borden; Philippe Solal-Celigny; Anton Hagenbeek; Richard I Fisher; Michael Unterhalt; R Arranz; T Chisesi; A Aviles; T Andrew Lister
Meta-analysis to evaluate the role of interferon in follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2215-23.
2005: Arun D Singh; Ernest C Borden
Metastatic uveal melanoma.
Ophthalmology clinics of North America 2005;18(1):143-50, ix.
2004: Todd W Kelley; Ernest C Borden; John R Goldblum
Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2004;12(4):338-41.
2004: Vadim Budagian; Elena Bulanova; Zane Orinska; Thomas Pohl; Ernest C Borden; Robert Silverman; Silvia Bulfone-Paus
Reverse signaling through membrane-bound interleukin-15.
The Journal of biological chemistry 2004;279(40):42192-201.
2004: Vadim Budagian; Elena Bulanova; Zane Orinska; Andreas Ludwig; Stefan Rose-John; Paul Saftig; Ernest C Borden; Silvia Bulfone-Paus
Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
The Journal of biological chemistry 2004;279(39):40368-75.
2004: Mamta Chawla-Sarkar; Soo In Bae; Frederic J Reu; Barbara S Jacobs; Daniel J Lindner; Ernest C Borden
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
Cell death and differentiation 2004;11(8):915-23.
2004: Xue-Fan Cui; Tadaatsu Imaizumi; Hidemi Yoshida; Ernest C Borden; Kei Satoh
Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells.
Biochemistry and cell biology = Biochimie et biologie cellulaire 2004;82(3):401-5.
2004: Maurie Markman; Jerome Belinson; Kenneth Webster; Kristine Zanotti; Bei Morrison; Barbara Jacobs; Ernest C Borden; Daniel J Lindner
Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.
Oncology 2004;66(5):343-6.
2003: Douglas W Leaman; Mamta Chawla-Sarkar; Barbara Jacobs; Keyur Vyas; Yaping Sun; Aylin Ozdemir; Taolin Yi; Bryan R Williams; Ernest C Borden
Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2003;23(12):745-56.
2003: Donna Glover; Joseph G Ibrahim; John Kirkwood; John Glick; Daniel Karp; James A Stewart; Marian Ewell; Ernest C Borden
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Melanoma research 2003;13(6):619-26.
2003: Mamta Chawla-Sarkar; John Anthony Bauer; Joseph A Lupica; Bei H Morrison; Zhuo Tang; Rhonda K Oates; alex almasan; Joseph A DiDonato; Ernest C Borden; Daniel J Lindner
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
The Journal of biological chemistry 2003;278(41):39461-9.
2003: Ernest C Borden; Laurence H Baker; Robert S Bell; Vivien Bramwell; George D Demetri; Burton L Eisenberg; Christopher D M Fletcher; Jonathan A Fletcher; Marc Ladanyi; Paul Meltzer; Brian O'Sullivan; David R Parkinson; Peter W T Pisters; Scott Saxman; Samuel Singer; Murali Sundaram; Allan T van Oosterom; Jaap Verweij; Jill Waalen; Sharon W Weiss; Murray F Brennan
Soft tissue sarcomas of adults: state of the translational science.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):1941-56.
2003: Mamta Chawla-Sarkar; Daniel J Lindner; Y-F Liu; B R Williams; G C Sen; R H Silverman; Ernest C Borden
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.
Apoptosis : an international journal on programmed cell death 2003;8(3):237-49.
2003: Michael P Malakhov; Keun Il Kim; Oxana A Malakhova; Barbara S Jacobs; Ernest C Borden; Dong-Er Zhang
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction.
The Journal of biological chemistry 2003;278(19):16608-13.
2003: Keyur Vyas; Diana L Brassard; Marc M DeLorenzo; Yaping Sun; Michael J Grace; Ernest C Borden; Douglas W Leaman
Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):202-11.
2003: Thomas E Hutson; Luis Molto; Tarek Mekhail; Paul Elson; James Finke; Charles S Tannenbaum; Ernest C Borden; Robert Dreicer; Thomas Olencki; Ronald M Bukowski
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1354-60.
2003: Paul Masci; Ronald M Bukowski; Phillip A Patten; Blaire L Osborn; Ernest C Borden
New and modified interferon alfas: preclinical and clinical data.
Current oncology reports 2003;5(2):108-13.
2003: John Anthony Bauer; Bei H Morrison; Ronald W Grane; Barbara S Jacobs; Ernest C Borden; Daniel J Lindner
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2003;23(1):3-10.
2002: Manas K Pathak; Deepika Dhawan; Daniel J Lindner; Ernest C Borden; Carol Farver; Taolin Yi
Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.
Molecular cancer therapeutics 2002;1(14):1255-64.
2002: Taolin Yi; Manas K Pathak; Daniel J Lindner; Michael E Ketterer; Carol Farver; Ernest C Borden
Anticancer activity of sodium stibogluconate in synergy with IFNs.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(10):5978-85.
2002: Ernest C Borden; John R Goldblum
Molecular characterization of soft tissue tumors.
Current oncology reports 2002;4(6):497-8.
2002: Douglas W Leaman; Mamta Chawla-Sarkar; Keyur Vyas; Monila Reheman; Katsuyuki Tamai; Singo Toji; Ernest C Borden
Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.
The Journal of biological chemistry 2002;277(32):28504-11.
2002: Mamta Chawla-Sarkar; Douglas W Leaman; Barbara S Jacobs; Ernest C Borden
IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(2):847-55.
2002: Paul Masci; Ernest C Borden
Malignant melanoma: treatments emerging, but early detection is still key.
Cleveland Clinic journal of medicine 2002;69(7):529, 533-4, 536-8 passim.
2002: Elisabetta Padovan; Luigi Terracciano; Ulrich Certa; Barbara Jacobs; Anca Reschner; Martin Bolli; Giulio C Spagnoli; Ernest C Borden; Michael Heberer
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells.
Cancer research 2002;62(12):3453-8.
2002: Mamta Chawla-Sarkar; Douglas W Leaman; Barbara S Jacobs; Ralph J Tuthill; Moitreyee Chatterjee-Kishore; George R Stark; Ernest C Borden
Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(5):603-13.
2001: RV Smalley; E Weller; M J Hawkins; M M Oken; M J O'Connell; S Haase-Statz; Ernest C Borden
Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
Leukemia 2001;15(7):1118-22.
2001: Mamta Chawla-Sarkar; Douglas W Leaman; Ernest C Borden
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1821-31.
2000: JA Sandberg; Vann P Parker; KS Blanchard; D Sweedler; J A Powell; A Kachensky; L Bellon; Nassim Usman; T Rossing; Ernest C Borden; Lawrence M Blatt
Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers.
Journal of clinical pharmacology 2000;40(12 Pt 2):1462-9.
2000: Ernest C Borden
Melanoma and pregnancy.
Seminars in oncology 2000;27(6):654-6.
2000: Ernest C Borden
Reducing primary melanoma mortality.
Current oncology reports 2000;2(4):289-91.
2000: Ernest C Borden; Daniel J Lindner; Robert Dreicer; M Hussein; David M Peereboom
Second-generation interferons for cancer: clinical targets.
Seminars in cancer biology 2000;10(2):125-44.
1999: Ernest C Borden; L Esserman; D J Linder; M J Campbell; A M Fulton
Biological therapies for breast carcinoma: concepts for improvement in survival.
Seminars in oncology 1999;26(4 Suppl 12):28-40.
1998: MA Rosenthal; M Green; P Wiernik; Ernest C Borden; J C Marsh; D G Haller
Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group.
American journal of clinical oncology 1998;21(5):509-12.
1998: Lawrence M Pfeffer; C A Dinarello; Ronald Herberman; B R Williams; Ernest C Borden; Ronald Bordens; Mark R Walter; TL Nagabhushan; PP Trotta; Sidney Pestka
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Cancer research 1998;58(12):2489-99.
1998: Mark R Walter; Ronald Bordens; TL Nagabhushan; B R Williams; Ronald Herberman; C A Dinarello; Ernest C Borden; PP Trotta; Sidney Pestka; Lawrence M Pfeffer
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.
Cancer biotherapy & radiopharmaceuticals 1998;13(3):143-54.
1998: Ernest C Borden; D Parkinson
A perspective on the clinical effectiveness and tolerance of interferon-alpha.
Seminars in oncology 1998;25(1 Suppl 1):3-8.
1998: Howard Hochster; Ruth Oratz; David S Ettinger; Ernest C Borden
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
Investigational new drugs 1998;16(3):259-63.
1998: Ernest C Borden
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta 1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers.
Pharmaceutical research 1998;15(1):2-3.
1997: Daniel J Lindner; Ernest C Borden
Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1997;17(11):681-93.
1997: Philip A Mackowiak; John G Bartlett; Ernest C Borden; Simeon E Goldblum; Jeffrey D Hasday; Robert Munford; S A Nasraway; PD Stolley; T E Woodward
Concepts of fever: recent advances and lingering dogma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(1):119-38.
1997: Daniel J Lindner; Ernest C Borden; Dhan V Kalvakolanu
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):931-7.
1997: Daniel J Lindner; Dhan V Kalvakolanu; Ernest C Borden
Increasing effectiveness of interferon-alpha for malignancies.
Seminars in oncology 1997;24(3 Suppl 9):S9-99-S9-104.
1997: Daniel J Lindner; Ernest C Borden
Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis.
International journal of cancer. Journal international du cancer 1997;71(3):456-61.
1997: A K Abdul-Ahad; A R Galazka; M Revel; Mauro Biffoni; Ernest C Borden
Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
Cytokines, cellular & molecular therapy 1997;3(1):27-32.
1997: John M Kirkwood; J Bryant; J H Schiller; M M Oken; Ernest C Borden; Theresa L Whiteside
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(2):146-57.
1997: Daniel J Lindner; V Kolla; Dhan V Kalvakolanu; Ernest C Borden
Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.
Molecular and cellular biochemistry 1997;167(1-2):169-77.
1996: Jerry L Taylor; J D'Cunha; P Tom; William J O'Brien; Ernest C Borden
Production of ISG-15, an interferon-inducible protein, in human corneal cells.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(11):937-40.
1996: Roger W. Byhardt; L Vaickus; P L Witt; ALEX CHANG; T McAuliffe; J Frank Wilson; Colleen A Lawton; J Breitmeyer; M E Alger; Ernest C Borden
Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(11):891-902.
1996: J D'Cunha; S Ramanujam; R J Wagner; P L Witt; E Knight; Ernest C Borden
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(9):4100-8.
1996: Ernest C Borden; S Wadler
Interferons as biochemical modulators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2627-30.
1996: Ernest C Borden; D Parkinson
Interferons: effectiveness, toxicities, and costs.
Annals of internal medicine 1996;125(7):614-6.
1996: P L Witt; S Zahir; P S Ritch; T M McAuliffe; C H Ewel; Ernest C Borden
Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(8):631-5.
1996: V Kolla; Daniel J Lindner; W Xiao; Ernest C Borden; Dhan V Kalvakolanu
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells.
The Journal of biological chemistry 1996;271(18):10508-14.
1996: Carolyn Keever-Taylor; P L Witt; Robert L Truitt; S Ramanujam; Ernest C Borden; P S Ritch
Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):231-43.
1996: J D'Cunha; E Knight; A L Haas; Robert L Truitt; Ernest C Borden
Immunoregulatory properties of ISG15, an interferon-induced cytokine.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(1):211-5.
1996: Joan H Schiller; M Pugh; J M Kirkwood; D Karp; M Larson; Ernest C Borden
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):29-36.
1996: Dhan V Kalvakolanu; Ernest C Borden
An overview of the interferon system: signal transduction and mechanisms of action.
Cancer investigation 1996;14(1):25-53.
1996: John M Kirkwood; M H Strawderman; Marc S Ernstoff; T J Smith; Ernest C Borden; Ronald Blum
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):7-17.
1996: D M Albert; L M Ryan; Ernest C Borden
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis.
Archives of ophthalmology 1996;114(1):107-8.
1995: C L Sivinski; Daniel J Lindner; Ernest C Borden; Margaret A Tempero
Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):156-65.
1995: Geoffrey Falkson; S Lipsitz; Ernest C Borden; I Simson; D Haller
Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril.
American journal of clinical oncology 1995;18(4):287-92.
1995: Ernest C Borden; J Waalen; R Schreiber; B Williams
Response and resistance to interferons and interacting cytokines.
Journal of the National Cancer Institute 1995;87(4):257-64.
1994: Ernest C Borden
Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma.
Seminars in oncology 1994;21(6 Suppl 14):14-22.
1994: Dhan V Kalvakolanu; S B Mannino; A Thornton; K Ozato; Ernest C Borden
Transcriptional induction of genes by IFN-beta in mouse cells is regulated by a transcription factor similar to human ISGF-3.
Antiviral research 1994;25(2):91-103.
1994: D M Moore; Dhan V Kalvakolanu; Scott M Lippman; John J Kavanagh; Waun Ki Hong; Ernest C Borden; M Paredes-Espinoza; I H Krakoff
Retinoic acid and interferon in human cancer: mechanistic and clinical studies.
Seminars in hematology 1994;31(4 Suppl 5):31-7.
1994: Ernest C Borden; P Chin
Interleukin-6: a cytokine with potential diagnostic and therapeutic roles.
The Journal of laboratory and clinical medicine 1994;123(6):824-9.
1993: Ernest C Borden; J Waalen; A M Liberati; F Grignani
Molecular diagnosis and monitoring of leukemia and lymphoma.
Leukemia research 1993;17(12):1073-8.
1993: P L Witt; P S Ritch; D Reding; T L McAuliffe; L Westrick; Sidney E Grossberg; Ernest C Borden
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Cancer research 1993;53(21):5176-80.
1993: W E Nolten; D Goldstein; M Lindstrom; M V McKenna; I H Carlson; D L Trump; J Schiller; Ernest C Borden; E N Ehrlich
Effects of cytokines on the pituitary-adrenal axis in cancer patients.
Journal of interferon research 1993;13(5):349-57.
1993: Ernest C Borden; R Lotan; D Levens; C W Young; S Waxman
Differentiation therapy of cancer: laboratory and clinical investigations.
Cancer research 1993;53(17):4109-15.
1993: Ernest C Borden; J Schlom
Williamsburg Conference on Biological and Immunological Treatments for Cancer, 1992.
Journal of the National Cancer Institute 1993;85(16):1288-93.
1993: D W Brar; Ernest C Borden; R A Proctor
Recombinant interferon-gamma preserves human granulocyte bactericidal and chemoluminescence activities.
The Journal of infectious diseases 1993;168(1):128-34.
1993: L Ryan; A Kramar; Ernest C Borden
Prognostic factors in metastatic melanoma.
Cancer 1993;71(10):2995-3005.
1993: P L Witt; Barry E Storer; G T Bryan; R R Brown; M Flashner; A T Larocca; C B Colby; Ernest C Borden
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):191-200.
1993: P L Witt; Isabelle J Marié; N Robert; A Irizarry; Ernest C Borden; Ara G Hovanessian
Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro.
Journal of interferon research 1993;13(1):17-23.
1993: C Gambacorti-Passerini; Jacquelyn A Hank; Mark R Albertini; A A Borchert; K H Moore; Joan H Schiller; R Bechhofer; Ernest C Borden; B Storer; Paul M Sondel
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):43-8.
1993: D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; Ernest C Borden; V C Jordan
Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Breast cancer research and treatment 1993;25(2):141-50.
1992: Ernest C Borden; K Kim; L Ryan; Ronald Blum; M Shiraki; D C Tormey; R L Comis; R G Hahn; D R Parkinson
Phase II trials of interferons-alpha and -beta in advanced sarcomas.
Journal of interferon research 1992;12(6):455-8.
1992: P L Witt; D Goldstein; Barry E Storer; Sidney E Grossberg; M Flashner; C B Colby; Ernest C Borden
Absence of biological effects of orally administered interferon-beta ser.
Journal of interferon research 1992;12(6):411-3.
1992: R V Smalley; J W Andersen; M J Hawkins; V Bhide; M J O'Connell; M M Oken; Ernest C Borden
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
The New England journal of medicine 1992;327(19):1336-41.
1992: Geoffrey Falkson; M Hunt; Ernest C Borden; J A Hayes; Carla Isadora Falkson; T J Smith
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Investigational new drugs 1992;10(4):337-43.
1992: R M Hansen; Ernest C Borden
Current status of interferons in the treatment of cancer.
Oncology (Williston Park, N.Y.) 1992;6(11):19-24; discussion 26, 29.
1992: G Schectman; S Kaul; R A Mueller; Ernest C Borden; Ahmed H Kissebah
The effect of interferon on the metabolism of LDLs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(9):1053-62.
1992: K Norioka; Ernest C Borden; R Auerbach
Inhibitory effects of cytokines on vascular endothelial cells: synergistic interactions among interferon-gamma, tumor necrosis factor-alpha, and interleukin-1.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(1):13-8.
1992: Y A Sidky; Ernest C Borden; C E Weeks; M J Reiter; J F Hatcher; G T Bryan
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Cancer research 1992;52(13):3528-33.
1992: Keith C Meyer; R Cornwell; J M Carlin; C Powers; A Irizarry; Gerald Byrne; Ernest C Borden
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide.
American journal of respiratory cell and molecular biology 1992;6(6):639-46.
1992: Ernest C Borden
Interferons--expanding therapeutic roles.
The New England journal of medicine 1992;326(22):1491-3.
1992: J A Merritt; L Andrew Ball; K M Sielaff; D M Meltzer; Ernest C Borden
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.
Journal of interferon research 1992;Spec No():7-16.
1992: John W Greiner; Fiorella Guadagni; D Goldstein; R V Smalley; Ernest C Borden; J F Simpson; A Molinolo; Jeffrey Schlom
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):735-46.
1992: Ernest C Borden
Interferons: pleiotropic cellular modulators.
Clinical immunology and immunopathology 1992;62(1 Pt 2):S18-24.
1992: Ernest C Borden
Cytokines and monoclonal antibodies: an introduction of their current and future applications to cancer and other diseases.
Medical Section proceedings : the ... annual Meeting of the Medical Section of the American Council of Life Insurance. American Council of Life Insurance. Medical Section. Meeting 1992;():51-62.
1991: Michael Recht; Ernest C Borden; E Knight
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(8):2617-23.
1991: D Goldstein; M O'Leary; J Mitchen; Ernest C Borden; George Wilding
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines.
The Journal of urology 1991;146(4):1173-7.
1991: Joan H Schiller; Mary J Lindstrom; P L Witt; J A Hank; David M Mahvi; R J Wagner; Paul M Sondel; Ernest C Borden
Immunological effects of levamisole in vitro.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):297-306.
1991: Keith C Meyer; C Powers; R Cornwell; Ernest C Borden
Priming of human alveolar macrophages and blood monocytes for superoxide anion release by interferons and lipopolysaccharide.
Journal of interferon research 1991;11(5):283-90.
1991: John W Greiner; Fiorella Guadagni; D Goldstein; Ernest C Borden; R E Ritts; P Witt; A F LoBuglio; M N Saleh; Jeffrey Schlom
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.
Cancer research 1991;51(16):4155-63.
1991: P L Witt; G T Spear; Mary J Lindstrom; Harold A Kessler; Ernest C Borden; J Phair; A L Landay
2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
AIDS (London, England) 1991;5(3):289-93.
1991: Ernest C Borden
Biotechnology: its impact on medicine and oncology.
Annals of the Academy of Medicine, Singapore 1991;20(2):255-9.
1991: John W Greiner; R V Smalley; Ernest C Borden; E W Martin; Fiorella Guadagni; Mario Roselli; Jeffrey Schlom
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.
Journal of surgical oncology. Supplement 1991;2():9-13.
1991: Y Ozaki; Ernest C Borden; R V Smalley; R R Brown
Interferon type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages.
Advances in experimental medicine and biology 1991;294():547-53.
1991: R R Brown; Y Ozaki; S P Datta; Ernest C Borden; Paul M Sondel; D G Malone
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Advances in experimental medicine and biology 1991;294():425-35.
1990: Ernest C Borden; J J Rinehart; Barry E Storer; D L Trump; Donna M Paulnock; A P Teitelbaum
Biological and clinical effects of interferon-beta ser at two doses.
Journal of interferon research 1990;10(6):559-70.
1990: D Goldstein; B Cheuvart; D L Trump; M Shiraki; R L Comis; D C Tormey; J E Harris; Ernest C Borden
Phase II trial of carboplatin in soft-tissue sarcoma.
American journal of clinical oncology 1990;13(5):420-3.
1990: Joan H Schiller; B Storer; Donna M Paulnock; R R Brown; S P Datta; P L Witt; Ernest C Borden
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
The Journal of clinical investigation 1990;86(4):1211-21.
1990: Ernest C Borden; D A Amato; J H Edmonson; P S Ritch; M Shiraki
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
Cancer 1990;66(5):862-7.
1990: Joan H Schiller; M A Horisberger; G Bittner; J M Carlin; B Storer; Gerald Byrne; James Willson; Ernest C Borden
Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
Journal of biological response modifiers 1990;9(4):368-77.
1990: D E Bergsagel; P von Wussow; R Alexanian; G Avvisati; R Bataille; Bart Barlogie; Ernest C Borden; F Caligaris-Cappio; H Deicher; B G Durie
Interferons in the treatment of multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(8):1444-5.
1990: P L Witt; G T Spear; D O Helgeson; Mary J Lindstrom; R V Smalley; Ernest C Borden
Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages.
Journal of interferon research 1990;10(4):393-402.
1990: Joan H Schiller; B Storer; P L Witt; B Nelson; R R Brown; M Horisberger; S Grossberg; Ernest C Borden
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Cancer research 1990;50(15):4588-94.
1990: Ernest C Borden; Stephen Creekmore
Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.
Cancer cells (Cold Spring Harbor, N.Y. : 1989) 1990;2(7):217-20.
1990: Michael G Rosenblum; W K Yung; P J Kelleher; F Ruzicka; PA Steck; Ernest C Borden
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Journal of interferon research 1990;10(2):141-51.
1990: Julie B Sedgwick; W E Frick; Paul M Sondel; J A Hank; Ernest C Borden; William W Busse
The appearance of hypodense eosinophils during interleukin-2 treatment.
The Journal of allergy and clinical immunology 1990;85(3):557-66.
1990: Ernest C Borden; Y A Sidky; E Ertürk; W Wierenga; G T Bryan
Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Cancer research 1990;50(4):1071-4.
1990: Ernest C Borden; Paul M Sondel
Lymphokines and cytokines as cancer treatment. Immunotherapy realized.
Cancer 1990;65(3 Suppl):800-14.
1990: D L Trump; Peter M Ravdin; Ernest C Borden; C F Magers; J K Whisnant
Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
Journal of biological response modifiers 1990;9(1):108-11.
1990: R H Earhart; D J Amato; ALEX CHANG; Ernest C Borden; M Shiraki; M E Dowd; R L Comis; T E Davis; T J Smith
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Investigational new drugs 1990;8(1):113-9.
1990: S P Robinson; D Goldstein; P L Witt; Ernest C Borden; V C Jordan
Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
Breast cancer research and treatment 1990;15(2):95-101.
1990: G J Litton; R Hong; S E Grossberg; D Vechlekar; C N Goodavish; Ernest C Borden
Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy.
Journal of biological response modifiers 1990;9(1):61-70.
1990: Joan H Schiller; S M Bushmeyer; F J Ruzicka; G L Princler; C R Faltynek; Ernest C Borden
Modulation of interferon receptor expression during combination beta ser-interferon and gamma-interferon treatment of human colon carcinoma cells.
Cancer research 1990;50(1):26-31.
1990: I B Rosenzweig; D A Wiebe; J A Hank; J J Albers; J L Adolphson; Ernest C Borden; E S Shrago; Paul M Sondel
Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein.
Biotherapy (Dordrecht, Netherlands) 1990;2(3):193-8.
1989: John L Schmitz; J M Carlin; Ernest C Borden; Gerald Byrne
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages.
Infection and immunity 1989;57(10):3254-6.
1989: A P Larocca; S C Leung; S G Marcus; C B Colby; Ernest C Borden
Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
Journal of interferon research 1989;9 Suppl 1():S51-60.
1989: M M Gottardis; R J Wagner; Ernest C Borden; V C Jordan
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
Cancer research 1989;49(17):4765-9.
1989: Donna M Paulnock; K A Havlin; B M Storer; G T Spear; K M Sielaff; Ernest C Borden
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
Journal of interferon research 1989;9(4):457-73.
1989: D Goldstein; K M Sielaff; Barry E Storer; R R Brown; S P Datta; P L Witt; A P Teitelbaum; R V Smalley; Ernest C Borden
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Journal of the National Cancer Institute 1989;81(14):1061-8.
1989: M Shiraki; H T Enterline; J J Brooks; N S Cooper; S Hirschl; J A Roth; U N Rao; F M Enzinger; D A Amato; Ernest C Borden
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience.
Cancer 1989;64(2):484-90.
1989: J M Carlin; Y Ozaki; Gerald Byrne; R R Brown; Ernest C Borden
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects.
Experientia 1989;45(6):535-41.
1989: Joan H Schiller; M J Hawkins; M J O'Connell; K Sielaff; Ernest C Borden
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Journal of biological response modifiers 1989;8(3):252-61.
1989: J M Carlin; Ernest C Borden; Gerald Byrne
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages.
Journal of interferon research 1989;9(3):329-37.
1989: D Goldstein; S M Bushmeyer; P L Witt; V C Jordan; Ernest C Borden
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.
Cancer research 1989;49(10):2698-702.
1989: Fiorella Guadagni; Jeffrey Schlom; W W Johnston; C A Szpak; D Goldstein; Richard E Smalley; J F Simpson; Ernest C Borden; S Pestka; John W Greiner
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
Journal of the National Cancer Institute 1989;81(7):502-12.
1989: J M Carlin; Ernest C Borden; Gerald Byrne
Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser.
Journal of interferon research 1989;9(2):167-73.
1989: H Ian Robins; K M Sielaff; B Storer; M J Hawkins; Ernest C Borden
Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
Cancer research 1989;49(6):1609-15.
1989: B E Nelson; Ernest C Borden
Interferons: biological and clinical effects.
Seminars in surgical oncology 1989;5(6):391-401.
1989: J M Carlin; Ernest C Borden; Paul M Sondel; Gerald Byrne
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.
Journal of leukocyte biology 1989;45(1):29-34.
1988: Joan H Schiller; B Storer; G Bittner; James Willson; Ernest C Borden
Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
Journal of interferon research 1988;8(5):581-9.
1988: Ernest C Borden; M J Hawkins; K M Sielaff; B M Storer; J D Schiesel; R V Smalley
Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial.
Journal of interferon research 1988;8(3):357-66.
1988: Y S Cheng; M F Becker-Manley; R G Rucker; Ernest C Borden
Accumulation of guanylate binding proteins in patients treated with interferons.
Journal of interferon research 1988;8(3):385-91.
1988: Ernest C Borden; Y A Sidky; J F Hatcher; G T Bryan
Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Cancer research 1988;48(9):2329-34.
1988: Ernest C Borden
Augmented tumor-associated antigen expression by interferons.
Journal of the National Cancer Institute 1988;80(3):148-9.
1988: K A Havlin; Anna D Inglot; James Willson; Ernest C Borden; S Grossberg; B Szulc; Andrzej Gladysz; B Groehlich
Lack of interferon production by dipyridamole.
Journal of interferon research 1988;8(2):135-6.
1988: G T Spear; Donna M Paulnock; D O Helgeson; Ernest C Borden
Requirement of differentiative signals of both interferon-gamma and 1,25-dihydroxyvitamin D3 for induction and secretion of interleukin-1 by HL-60 cells.
Cancer research 1988;48(7):1740-4.
1988: Ernest C Borden; E C Bradley; C H Evans; C F Fox; R S Metzgar; M S Mitchell; J N Weinstein
Biotechnology products in cancer therapy: a colloquium.
Cancer research 1988;48(1):223-5.
1988: Ernest C Borden
Effects of interferons in neoplastic diseases of man.
Pharmacology & therapeutics 1988;37(2):213-29.
1987: F J Ruzicka; M E Jach; Ernest C Borden
Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains.
The Journal of biological chemistry 1987;262(33):16142-9.
1987: Joan H Schiller; B Storer; James Willson; Ernest C Borden
Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Cancer treatment reports 1987;71(10):945-52.
1987: I B Rosenzweig; D A Wiebe; Ernest C Borden; B Storer; E S Shrago
Plasma lipoprotein changes in humans induced by beta-interferon.
Atherosclerosis 1987;67(2-3):261-7.
1987: Ernest C Borden; I B Rosenzweig; Gerald Byrne
Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism.
Journal of interferon research 1987;7(5):591-6.
1987: J M Carlin; Ernest C Borden; Paul M Sondel; Gerald Byrne
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(7):2414-8.
1987: Y A Sidky; Ernest C Borden
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.
Cancer research 1987;47(19):5155-61.
1987: M W Konrad; A L Childs; T C Merigan; Ernest C Borden
Assessment of the antigenic response in humans to a recombinant mutant interferon beta.
Journal of clinical immunology 1987;7(5):365-75.
1987: F J Ruzicka; S M Schmid; D S Groveman; K B Cummings; Ernest C Borden
Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
Cancer research 1987;47(17):4582-9.
1987: G T Spear; Donna M Paulnock; R L Jordan; D M Meltzer; J A Merritt; Ernest C Borden
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.
Clinical and experimental immunology 1987;69(1):107-15.
1987: Ernest C Borden; D A Amato; C Rosenbaum; H T Enterline; M J Shiraki; R H Creech; H J Lerner; P P Carbone
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(6):840-50.
1987: G Falkson; D A Vorobiof; I W Simson; Ernest C Borden
Phase II trial of acivicin in malignant mesothelioma.
Cancer treatment reports 1987;71(5):545-6.
1987: Ernest C Borden
Progress in management of malignant melanoma.
Wisconsin medical journal 1987;86(4):23-5.
1987: D L Trump; P J Elson; Ernest C Borden; J E Harris; R L Tuttle; J K Whisnant; M M Oken; J R Carignan; John Ruckdeschel; T E Davis
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
Cancer treatment reports 1987;71(2):165-9.
1987: D A Amato; H Bruckner; D Guerry; A Ash; G Falkson; Ernest C Borden; R H Creech; E D Savlov; T J Cunningham
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Investigational new drugs 1987;5(3):293-7.
1987: M K Samson; L P Wasser; Ernest C Borden; H J Wanebo; R H Creech; M Phillips; Laurence H Baker
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):86-91.
1987: J P Kuebler; T D Oberley; L F Meisner; Y A Sidky; C A Reznikoff; Ernest C Borden; K B Cummings; G T Bryan
Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells.
Investigational new drugs 1987;5(1):21-9.
1986: E R Massaro; Ernest C Borden; M J Hawkins; D A Wiebe; E Shrago
Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition.
Journal of interferon research 1986;6(6):655-62.
1986: Joan H Schiller; James Willson; G Bittner; W H Wolberg; M J Hawkins; Ernest C Borden
Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay.
Journal of interferon research 1986;6(6):615-25.
1986: B S Edwards; R C Fuhlbrigge; Ernest C Borden
Separation of human natural killer cell subpopulations differentially responsive to interferon potentiation.
Journal of interferon research 1986;6(4):361-72.
1986: Y A Sidky; Ernest C Borden; W Wierenga; G T Bryan
Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors.
Cancer research 1986;46(8):3798-802.
1986: Gerald Byrne; L K Lehmann; J G Kirschbaum; Ernest C Borden; C M Lee; R R Brown
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity.
Journal of interferon research 1986;6(4):389-96.
1986: J A Merritt; L Andrew Ball; K M Sielaff; D M Meltzer; Ernest C Borden
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.
Journal of interferon research 1986;6(3):189-98.
1986: Ernest C Borden; M J Hawkins
Biologic response modifiers as adjuncts to other therapeutic modalities.
Seminars in oncology 1986;13(2):144-52.
1986: J R Quesada; R Alexanian; M Hawkins; Bart Barlogie; Ernest C Borden; L Itri; Jordan U Gutterman
Treatment of multiple myeloma with recombinant alpha-interferon.
Blood 1986;67(2):275-8.
1986: J H Schiller; D S Groveman; S M Schmid; James Willson; K B Cummings; Ernest C Borden
Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis.
Cancer research 1986;46(2):483-8.
1986: ALEX CHANG; J P Kuebler; D C Tormey; S Anderson; K J Pandya; Ernest C Borden; T E Davis; D L Trump
Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer.
Cancer 1986;57(1):54-9.
1986: J C Arseneau; David Schoenfeld; Ernest C Borden
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Investigational new drugs 1986;4(1):53-6.
1986: R V Smalley; Ernest C Borden
Interferons: current status and future directions of this prototypic biological.
Springer seminars in immunopathology 1986;9(1):73-83.
1985: Ernest C Borden; A K Verma; W H Wolberg
Potential role of polyribonucleotides in human neoplastic diseases.
Journal of biological response modifiers 1985;4(6):676-9.
1985: M J Hawkins; M Levin; Ernest C Borden
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
Journal of biological response modifiers 1985;4(6):664-8.
1985: B S Edwards; J A Merritt; R C Fuhlbrigge; Ernest C Borden
Low doses of interferon alpha result in more effective clinical natural killer cell activation.
The Journal of clinical investigation 1985;75(6):1908-13.
1985: J A Merritt; Ernest C Borden; L Andrew Ball
Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.
Journal of interferon research 1985;5(1):191-8.
1985: Ernest C Borden; Y A Sidky; D S Groveman; G T Bryan
Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide.
Cancer research 1985;45(1):45-50.
1985: J A Merritt; D M Meltzer; L Andrew Ball; Ernest C Borden
2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
Progress in clinical and biological research 1985;202():423-30.
1985: D A Amato; Ernest C Borden; M Shiraki; H T Enterline; C Rosenbaum; H L Davis; A R Paul; C M Stevens; H J Lerner
Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Investigational new drugs 1985;3(4):397-401.
1984: M J Hawkins; Susan E Krown; Ernest C Borden; M Krim; F X Real; B S Edwards; S A Anderson; S Cunningham-Rundles; H F Oettgen
American cancer society Phase I trial of naturally produced beta-interferon.
Cancer research 1984;44(12 Pt 1):5934-8.
1984: D S Groveman; Ernest C Borden; J A Merritt; H I Robins; R Steeves; G T Bryan
Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines.
Cancer research 1984;44(12 Pt 1):5517-21.
1984: Ernest C Borden
Progress toward therapeutic application of interferons, 1979-1983.
Cancer 1984;54(11 Suppl):2770-6.
1984: Ernest C Borden; D S Groveman; T Nasu; C Reznikoff; G T Bryan
Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro.
The Journal of urology 1984;132(4):800-3.
1984: B S Edwards; M J Hawkins; Ernest C Borden
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Cancer research 1984;44(7):3135-9.
1984: B S Edwards; J A Merritt; P A Jelen; Ernest C Borden
Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(6):2868-75.
1984: R M Dixon; Ernest C Borden; N L Keim; S Anderson; T L Spennetta; D C Tormey; E Shrago
Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons.
Metabolism: clinical and experimental 1984;33(5):400-4.
1984: M J Hawkins; Ernest C Borden; J A Merritt; B S Edwards; L Andrew Ball; E Grossbard; K J Simon
Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(3):221-6.
1984: Ernest C Borden; F R Balkwill
Preclinical and clinical studies of interferons and interferon inducers in breast cancer.
Cancer 1984;53(3 Suppl):783-9.
1984: M N Gould; R C Kakria; S Olson; Ernest C Borden
Radiosensitization of human bronchogenic carcinoma cells by interferon beta.
Journal of interferon research 1984;4(1):123-8.
1984: R C Fuhlbrigge; B S Edwards; Ernest C Borden
Effects of interferon alpha on the sheep erythrocyte "receptor" of human lymphocytes.
Journal of interferon research 1984;4(4):499-505.
1984: James Willson; G Bittner; Ernest C Borden
Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay.
Journal of interferon research 1984;4(4):441-7.
1983: H J Lerner; David Schoenfeld; A Martin; G Falkson; Ernest C Borden
Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.
Cancer 1983;52(11):1981-5.
1983: R H Earhart; J M Koeller; T E Davis; Ernest C Borden; J P McGovren; H L Davis; D C Tormey
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.
Cancer treatment reports 1983;67(7-8):683-92.
1983: William W Busse; C A Swenson; Ernest C Borden; M W Treuhaft; E C Dick
Effect of influenza A virus on leukocyte histamine release.
The Journal of allergy and clinical immunology 1983;71(4):382-8.
1983: B S Edwards; M J Hawkins; Ernest C Borden
Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Journal of biological response modifiers 1983;2(5):409-17.
1983: D S Groveman; Ernest C Borden
In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma.
Journal of biological response modifiers 1983;2(2):167-74.
1983: T F Hogan; B L Padgett; D L Walker; Ernest C Borden; Z Frias
Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma.
Progress in clinical and biological research 1983;105():311-24.
1983: Ernest C Borden
Interferons and cancer: how the promise is being kept.
Interferon 1983;5():43-83.
1983: Ernest C Borden
Interferons: in pursuit of the promise.
Progress in clinical and biological research 1983;132E():287-96.
1982: Ernest C Borden; T F Hogan; J G Voelkel
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.
Cancer research 1982;42(12):4948-53.
1982: M Liberati; Ernest C Borden; J A McBain; R Raubertas
Effects of levamisole on human natural killer and killer cell activity and production of interferons.
Immunopharmacology 1982;5(1):11-8.
1982: Ernest C Borden; A Ash; H T Enterline; C Rosenbaum; J F Laucius; A R Paul; G Falkson; H Lerner
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
American journal of clinical oncology 1982;5(4):417-20.
1982: Ernest C Borden; J F Holland; T L Dao; J U Gutterman; L Wiener; Y C Chang; J Patel
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.
Annals of internal medicine 1982;97(1):1-6.
1982: A M Liberati; J G Voelkel; Ernest C Borden; A S Coates; D L Citrin; G T Bryan
Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma.
Cancer immunology, immunotherapy : CII 1982;13(2):140-4.
1982: B S Edwards; Ernest C Borden; K Smith-Zaremba
Divergence in activation by poly I:C of human natural killer and killer cells.
Cancer immunology, immunotherapy : CII 1982;13(3):158-63.
1981: N E Mischler; D C Tormey; J Klotz; Ernest C Borden; G Ramirez; T K Banerjee; R M Carr; S D Zaentz; J Graf
Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas.
Cancer clinical trials 1981;4(4):407-10.
1981: Ernest C Borden; J A McBain; J Martin; D Walker
Augmentation in the infectivity of SV40 virus DNA by amphotericin B methyl ester: brief report.
Archives of virology 1981;69(2):161-5.
1981: Ernest C Borden
Cellular modulation of induction by polyribonucleotides of interferons.
Texas reports on biology and medicine 1981;41():122-8.
1981: Ernest C Borden; L A Ball
Interferons: biochemical, cell growth inhibitory, and immunological effects.
Progress in hematology 1981;12():299-339.
1980: Ernest C Borden; M J Hawkins
Interferons for human neoplastic and viral diseases.
Comprehensive therapy 1980;6(10):6-15.
1980: Joseph J Esposito; E L Palmer; Ernest C Borden; A K Harrison; J F Obijeski; Frederick A Murphy
Studies on the poxvirus Cotia.
The Journal of general virology 1980;47(1):37-46.
1980: T F Hogan; Ernest C Borden; J A McBain; B L Padgett; D L Walker
Human polyomavirus infections with JC virus and BK virus in renal transplant patients.
Annals of internal medicine 1980;92(3):373-8.
1980: T F Hogan; B L Padgett; D L Walker; Ernest C Borden; J A McBain
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy.
Journal of clinical microbiology 1980;11(2):178-83.
1979: Ernest C Borden
Interferons: rationale for clinical trials in neoplastic disease.
Annals of internal medicine 1979;91(3):472-9.
1979: Ernest C Borden; J A McBain; P H Leonhardt
Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid.
Antimicrobial agents and chemotherapy 1979;16(2):203-9.
1979: J M Zarling; L Eskra; Ernest C Borden; J Horoszewicz; W A Carter
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon.
Journal of immunology (Baltimore, Md. : 1950) 1979;123(1):63-70.
1979: Ernest C Borden; B W Booth; J A McBain
Enhancement of infectivity of encephalomyocarditis virus RNA by amphotericin B methyl ester.
The Journal of general virology 1979;42(2):297-303.
1978: T F Hogan; D L Citrin; B M Johnson; S Nakamura; T E Davis; Ernest C Borden
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Cancer 1978;42(5):2177-81.
1978: J M Zarling; Jeffrey A Sosman; L Eskra; Ernest C Borden; J S Horoszewicz; W A Carter
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon.
Journal of immunology (Baltimore, Md. : 1950) 1978;121(5):2002-4.
1978: B W Booth; Ernest C Borden
Increase by calcium in production of interferon by L929 cells induced with polyriboinosinate-polyribocytidylate complex.
The Journal of general virology 1978;40(2):485-8.
1978: Ernest C Borden
Synergistic cytotoxicity for L929 cells of polyriboinosinic-polyribocytidylic acid and amphotericin B methyl ester.
Journal of the National Cancer Institute 1978;60(6):1309-11.
1978: Ernest C Borden; B W Booth; P H Leonhardt
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid.
Antimicrobial agents and chemotherapy 1978;13(2):159-64.
1977: Ernest C Borden; P H Leonhardt
Aquanititave semimicro, semiautomated colorimetric assay for interferon.
The Journal of laboratory and clinical medicine 1977;89(5):1036-42.
1977: Ernest C Borden; P Larson; F J Ansfield; G T Bryan; R O Johnson; G Ramirez; W L Wilson
Hexamethylmelamine treatment of sarcomas and lymphomas.
Medical and pediatric oncology 1977;3(4):401-6.
1976: F J Ansfield; H L Davis; G Ramirez; T E Davis; Ernest C Borden; R O Johnson; G T Bryan
Further clinical studies with megestrol acetate in advanced breast cancer.
Cancer 1976;38(1):53-5.
1976: Ernest C Borden; P H Leonhardt
Enhancement of rIn:rCn-induced interferon production by amphotericin B.
Antimicrobial agents and chemotherapy 1976;9(3):551-3.
1975: F J Ansfield; G Ramirez; H L Davis; G W Wirtanen; R O Johnson; G T Bryan; F B Manalo; Ernest C Borden; T E Davis; M Esmili
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil.
Cancer 1975;36(6 Suppl):2413-7.
1975: Ernest C Borden; E V Prochownik; W A Carter
The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein.
Journal of immunology (Baltimore, Md. : 1950) 1975;114(2 pt 2):752-6.
1974: Ernest C Borden; W A Carter; L L Sensenbrenner; A H Owens; J Lichtenstein; G D Gray; G L Neil; F R Nichol; L H Li
Inhibition by streptovaricins of Rauscher leukemia virus splenomegaly.
International journal of cancer. Journal international du cancer 1974;14(6):817-25.
1974: Ernest C Borden; N Nathanson
Tacaribe virus infection of the mouse: an immunopathologic disease model.
Laboratory investigation; a journal of technical methods and pathology 1974;30(4):465-73.
1974: Ernest C Borden; E R Baker; M D Abeloff
Symposium on breast cancer. Introduction.
The Johns Hopkins medical journal 1974;134(2):65.
1974: Ernest C Borden
Viruses and breast cancer: implications of mouse and human studies.
The Johns Hopkins medical journal 1974;134(2):66-76.
1972: Ernest C Borden; W A Carter
Viral chemotherapy: its promise and problems.
Medicine 1972;51(3):189-90.
1972: W A Carter; PAULA PITHA-ROWE; W W Brockman; Ernest C Borden; L W Marshall
Selective inhibition of viral functions: the antiviral action of interferon and streptovaricin.
Medicine 1972;51(3):181-8.
1971: Frederick A Murphy; Ernest C Borden; R E Shope; A Harrison
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies.
The Journal of general virology 1971;13(2):273-88.
1971: Ernest C Borden; R E Shope; Frederick A Murphy
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies.
The Journal of general virology 1971;13(2):261-71.
1971: Ernest C Borden; W W Brockman; W A Carter
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus.
Nature: New biology 1971;232(33):214-6.
1971: W A Carter; W W Brockman; Ernest C Borden
Streptovaricins inhibit focus formation by MSV (MLV) complex.
Nature: New biology 1971;232(33):212-4.
1971: T P Monath; Ernest C Borden
Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice.
The Journal of infectious diseases 1971;123(3):297-300.
1971: Ernest C Borden; Frederick A Murphy
The interferon refractory state: in vivo and in vitro studies of its mechanism.
Journal of immunology (Baltimore, Md. : 1950) 1971;106(1):134-42.
1970: Ernest C Borden; G W Gary; Frederick A Murphy
Comparison of agar and agarose preparations for mengovirus plaque formation.
Applied microbiology 1970;20(2):289-91.
1970: Ernest C Borden; Frederick A Murphy; G W Gary
Attempted suppression of the interferon response in the mouse.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1970;134(3):865-9.
1969: Ernest C Borden; Frederick A Murphy
Depression of interferon production after A.L.S. treatment.
Lancet 1969;2(7633):1307-8.
1969: Ernest C Borden; H E Holling
Hypertrophic osteoarthropathy and pregnancy.
Annals of internal medicine 1969;71(3):577-80.
1968: Ernest C Borden; S G Rostand
Recovery from massive amitriptyline overdosage.
Lancet 1968;1(7554):1256.
1967: Ernest C Borden
John Locke, physician and author of the first Carolina Constitution.
Southern medical journal 1967;60(3):283-8.